

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 February 2009 (05.02.2009)

PCT

(10) International Publication Number  
**WO 2009/018226 A3**

(51) International Patent Classification:  
C07K 16/28 (2006.01) C07K 16/42 (2006.01)

(21) International Application Number:  
PCT/US2008/071379

(22) International Filing Date: 28 July 2008 (28.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/952,328 27 July 2007 (27.07.2007) US

(71) Applicant (for all designated States except US): **FACTET BIOTECH CORPORATION** [US/US]; 1500 Seaport Boulevard, Redwood City, CA 94063 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMAKRISHNAN, Vanitha** [US/US]; 825 Holly Road, Belmont, California 94002 (US). **BHASKAR, Vinay** [US/US]; 1712 Castro Street, San Francisco, California 94131 (US).

(74) Agent: **DOW, Karen, B.**; DLA Piper LLP (US), 4365 Executive Drive, Suite 1100, San Diego, CA 92121-2133 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:  
2 April 2009

(54) Title: PHARMACEUTICAL COMBINATIONS COMPRISING A TYROSINE KINASE INHIBITOR AND AN ANTIBODY AGAINST INTEGRIN ALPHA 1 BETA 5 (CD49E)

(57) Abstract: Pharmaceutical combinations comprising an  $\alpha 5\beta 1$  antagonist in combination with a tyrosine kinase inhibitor. In some embodiments, the  $\alpha 5\beta 1$  antagonist is volociximab. In some embodiments, the tyrosine kinase inhibitor is sunitinib or a pharmaceutically acceptable salt thereof. The invention also relates to methods for treating cancer by administering the pharmaceutical combinations to a subject.



WO 2009/018226 A3

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/US2008/071379

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C07K16/28 C07K16/42

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/056308 A (PROTEIN DESIGN LABS INC [US]; RAMAKRISHNAN VANITHA [US]; POWERS DAVID) 8 July 2004 (2004-07-08) paragraph [0009] paragraph [0090] - paragraph [0100] claims; examples  ----- -/--	1-20

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

5 February 2009

Date of mailing of the international search report

13/02/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Rankin, Robert

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/071379

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MATAR PABLO ET AL: "Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting"            CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 19,            1 October 2004 (2004-10-01), pages 6487-6501, XP002418718            ISSN: 1078-0432            the whole document</p>	1-20
A	<p>WO 2005/092073 A (PROTEIN DESIGN LABS INC [US]; RAMAKRISHNAN VANITHA [US]; BHASKAR VINAY) 6 October 2005 (2005-10-06)            page 7, line 22 - line 31            claims; examples</p>	1-20
A	<p>RAMAKRISHNAN V ET AL: "Preclinical evaluation of an anti-<math>\alpha</math>5<math>\beta</math>1 integrin antibody as a novel anti-angiogenic agent"            JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB,            vol. 5, no. 4, 4 May 2006 (2006-05-04), pages 273-286, XP008081487            ISSN: 1359-4117            the whole document</p>	1-20
A	<p>KUWADA S K: "Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody"            CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB,            vol. 9, no. 1,            1 January 2007 (2007-01-01), pages 92-98, XP008081479            ISSN: 1464-8431            the whole document</p>	1-20
P,A	<p>BHASKAR VINAY ET AL: "A function blocking anti-mouse integrin <math>\alpha</math>5<math>\beta</math>1 antibody inhibits angiogenesis and impedes tumor growth in vivo."            JOURNAL OF TRANSLATIONAL MEDICINE 2007, vol. 5, 2007, page 61, XP021037644            ISSN: 1479-5876</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2008/071379
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004056308 A	08-07-2004	AU 2003298783 A1	14-07-2004
		BR 0316670 A	11-10-2005
		CA 2507099 A1	08-07-2004
		CN 1753911 A	29-03-2006
		EP 1575516 A2	21-09-2005
		JP 2006516098 T	22-06-2006
		KR 20050089151 A	07-09-2005
		MX PA05005558 A	26-07-2005
		NZ 540562 A	30-04-2008
WO 2005092073 A	06-10-2005	AU 2005226736 A1	06-10-2005
		BR PI0509177 A	18-09-2007
		CA 2560508 A1	06-10-2005
		EP 1755659 A2	28-02-2007
		JP 2007530584 T	01-11-2007
		KR 20070009637 A	18-01-2007